Skip to content
Screener

Summit Therapeutics SMMT Common stock, par value (in dollars per share)

Common stock, par value (in dollars per share) at other companies

Arcus Biosciences logo
Arcus BiosciencesRCUS
$00.0%
Exelixis logo
ExelixisEXEL
$00.0%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
Incyte logo
IncyteINCY

Other financials

Income statement

See full
Revenue-
Operating income-$65.6M-81.2%
Net income-$189.4M-201%
EPS (diluted)-$0.24-167%

Balance sheet

See full
Cash & equivalents$8.2M+7.2%
Total debt$20.0M+211%
Total equity$545.9M+58.5%
Total assets$647.9M+68.8%

Cash flow

See full
Operating cash flow-$122.3M-99.9%
CapEx$245.0K-41.9%
Free cash flow-$122.5M-99.0%

Valuation

See full
Market cap$11.14B-43.5%
Enterprise value$11.15B-43.4%

Profitability

See full
Operating margin-268,266.8%-272,316pp
Net margin-271,685%-275,966pp
FCF margin-5,931.6%+4,730pp

Returns & leverage

See full
Return on equity-271%-1,725pp
Debt / equity0.0×
Current ratio7.4×-3.2×

Where this comes from

Reported directly by Summit Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.

The source filing: Summit Therapeutics’s 10-Q, filed April 30, 2026.

Filed
Apr 30, 2026, 5:00 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001599298-26-000039
Line itemMarch 31, 2026December 31, 2025
Commitments and contingencies (Note 12)
Stockholders' equity:
Preferred stock, $0.01 par value, 20,000,000 shares authorized; none issued and outstanding at March 31, 2026 and December 31, 2025, respectively
Common stock, $0.01 par value: 1,000,000,000 shares authorized; 776,017,474 and 775,371,200 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively7,7607,754
Additional paid-in capital3,024,3872,947,805
Accumulated other comprehensive loss(2,632)(2,540)
Accumulated deficit(2,483,583)(2,294,159)
Total stockholders' equity545,932658,860

Item 1. Financial Statements.

FAQ

What is Summit Therapeutics's common stock, par value (in dollars per share)?
Summit Therapeutics (SMMT) reported common stock, par value (in dollars per share) of $0.01 in Q1 2026.
How has Summit Therapeutics's common stock, par value (in dollars per share) changed year-over-year?
Summit Therapeutics's common stock, par value (in dollars per share) decreased by 0.0% year-over-year, from $0.01 to $0.01.
What is the long-term trend for Summit Therapeutics's common stock, par value (in dollars per share)?
Over 5 years (2020 to 2025), Summit Therapeutics's common stock, par value (in dollars per share) has grown at a 0.0% compound annual growth rate (CAGR), from $0.01 to $0.01.

Ask your AI about Summit Therapeutics's common stock, par value (in dollars per share).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude